How golden is the gold standard of neuropathology in dementia?
暂无分享,去创建一个
[1] Carol Brayne,et al. Age, neuropathology, and dementia. , 2009, The New England journal of medicine.
[2] M. Esiri,et al. Pro: Can neuropathology really confirm the exact diagnosis? , 2010, Alzheimer's Research & Therapy.
[3] K. Rockwood. Con: Can biomarkers be gold standards in Alzheimer's disease? , 2010, Alzheimer's Research & Therapy.
[4] W. M. van der Flier,et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.
[5] Marshall Godwin,et al. Health measurement scales , 1991 .
[6] K. Jellinger. Con: Can neuropathology really confirm the exact diagnosis? , 2010, Alzheimer's Research & Therapy.
[7] Andrew King,et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. , 2009, Acta neuropathologica.
[8] Keith A. Johnson,et al. Pro: Can biomarkers be gold standards in Alzheimer's disease? , 2010, Alzheimer's Research & Therapy.
[9] L. White. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. , 2009, Journal of Alzheimer's disease : JAD.
[10] Ian G. McKeith,et al. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.
[11] Susan M Resnick,et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.
[12] J. Price,et al. Interlaboratory Histopathologic Assessment of Alzheimer Neuropathology: Different Methodologies Yield Comparable Diagnostic Results , 1993, Alzheimer disease and associated disorders.
[13] B. Crain,et al. Interlaboratory Comparison of Neuropathology Assessments in Alzheimer's Disease: A Study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Journal of neuropathology and experimental neurology.
[14] K. Jellinger,et al. Interrater reliability in the neuropathologic diagnosis of Alzheimer's disease , 1992, Neurology.
[15] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[16] W. Schlote,et al. Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories A European multicenter study under the auspices of EURAGE , 1990, Journal of the Neurological Sciences.
[17] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[18] G. B. Frisoni,et al. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.
[19] H. Braak,et al. Staging of Alzheimer-type pathology: an interrater-intrarater study. , 1997, Dementia and geriatric cognitive disorders.
[20] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.